^
Association details:
| Biomarker: | PD-L1 expression |
|---|---|
| Cancer: | Solid Tumor |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) + favezelimab (MK-4280) (LAG-3 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Phase 1 trial of the anti-LAG3 antibody favezelimab plus pembrolizumab in advanced gastric cancer.
Published date:
01/17/2023
Excerpt:
In 2 arms, higher dose of fave (700mg) showed increased ORR and 12 months PFS rate….Favezelimab alone or in combination with pembrolizumab had an acceptable safety profile. The combination therapy showed antitumor activity in line with other checkpoint inhibitors in advanced gastric cancer though higher antitumor activity was seen in PDL1 CPS≥ 1 tumors, particularly at higher dose.
DOI:
10.1200/JCO.2023.41.3_suppl.394
Trial ID:
